Dermapharm Holding SE engages in the development, manufacture and market of patent-free pharmaceutical products. The company is headquartered in Gruenwald, Bayern and currently employs 3,610 full-time employees. The company went IPO on 2018-02-09. The firm operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. The company holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The firm offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. The company is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.
¿Qué tal es el rendimiento del precio de la acción DERMAPHARM HLDG SE?
El precio actual de DERMAPHARM HLDG SE es de $39.56, ha disminuido un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Dermapharm Holding SE?
Dermapharm Holding SE pertenece a la industria Pharmaceuticals y el sector es Health Care
¿Cuál es la capitalización bursátil de Dermapharm Holding SE?
La capitalización bursátil actual de Dermapharm Holding SE es $2.1B
¿Es Dermapharm Holding SE una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 6 analistas han realizado calificaciones de análisis para Dermapharm Holding SE, incluyendo 2 fuerte compra, 6 compra, 3 mantener, 0 venta, y 2 fuerte venta